NeoGenomics Inc. (NASDAQ:NEO) is one of the most buzzing stocks to buy with the highest upside potential. On February 25, ...

NeoGenomics, Inc. recently announced that its PanTracer LBx liquid biopsy test has received Medicare coverage under the MolDX Plasma-Based Genomic Profiling in Solid Tumors policy, allowing eligible ...

NeoGenomics has seen a strong start to the year. The Fort Myers-based cancer testing and research lab reported revenue growth of 8% in the first quarter over the year. Revenue rose from roughly $156.2 ...

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran ...

FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a ...

NeoGenomics (NASDAQ:NEO) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement. Analysts estimate that NeoGenomics will ...

NeoGenomics (NEO) moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026 FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ:NEO), a ...

Southwest Florida companies Hertz, Herc, NeoGenomics, and Alico report Q4 and full-year 2025 earnings, showing mixed results.

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NeoGenomics, Inc. (NASDAQ: NEO) securities between February 27, 2020 and April 26, 2022, ...